Evidence map›Paper›PMID 37652453›Full record

ArticleThe Journal of international medical research2023

Efficacy of subthreshold micropulse laser photocoagulation therapy versus anti-vascular endothelial growth factor therapy for refractory macular edema secondary to non-ischemic branch retinal vein occlusion.

Xiaoxiao Feng, Yunqin Li, Min Wu, Aihua Dan, Wenzhi Yang, Yali Peng, Libo Xiao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiaoxiao FengDepartment of Ophthalmology, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.ORCID 0000-0002-8538-7069
Yunqin LiDepartment of Ophthalmology, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Min WuDepartment of Ophthalmology, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Aihua DanDepartment of Ophthalmology, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Wenzhi YangDepartment of Ophthalmology, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Yali PengDepartment of Ophthalmology, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Libo XiaoDepartment of Ophthalmology, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Yunnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the efficacy of subthreshold micropulse laser photocoagulation (SMLP) therapy versus anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with refractory macular edema (ME) secondary to non-ischemic branch retinal vein occlusion (BRVO).

methodsThis single-center, prospective, nonrandomized, case-control trial involved patients with refractory ME that responded poorly to three or more initial anti-VEGF injections. The patients were examined and divided into two groups according to their chosen treatment: the intravitreal ranibizumab (IVR) group and the SMLP group. Both groups were followed up monthly for 12 months. Therapeutic efficacy and safety were assessed throughout the follow-up period.

resultsThe IVR group comprised 49 eyes, and the SMLP group comprised 45 eyes. The improvements in the optical coherence tomography findings and visual acuity were comparable between the two groups at the final follow-up. The total number of injections was significantly lower in the SMLP than IVR group. No serious adverse events occurred during the study period.

conclusionsSMLP therapy is better for patients with central macular thickness (CMT) of ≤400 μm. For patients with CMT of >400 μm, we advise continuation of anti-VEGF agents to reduce ME followed by application of SMLP therapy when CMT has decreased to ≤400 μm.

Indexed as

Macular EdemaRetinal Vein OcclusionEndothelial Growth FactorsHumansLasersLight CoagulationProspective StudiesEndothelial Growth Factorsanti-vascular endothelial growth factorbranch retinal vein occlusioncentral macular thicknessintravitreous drug injectionoptical coherence tomographyrefractory macular edemaSubthreshold micropulse laser photocoagulation

Identifiers

PMID37652453
PMCPMC10478568
OpenAlexW4386319562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.